ImmunoGen, Inc. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/6986b3b2-7946-45b7-a0c0-f42137b2a925/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-222.9M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002558 |
| FY 2021 | $-139.3M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002358 |
| FY 2020 | $-44.4M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002170 |
| FY 2019 | $4.8M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-005161 |
| FY 2018 | $-168.8M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-001432 |
| FY 2017 | $-96.0M | 2017-01-01 – 2017-12-31 | evidence 0001558370-18-001641 |
| FY 2016 | $-156.7M | 2016-01-01 – 2016-12-31 | evidence 0001558370-18-001641 |
| FY 2015 | $-60.7M | 2014-07-01 – 2015-06-30 | evidence 0001558370-18-001641 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).